ethyl 2-(benzylamino)thiazole-4-carboxylate | 126534-13-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: ethyl 2-(benzylamino)thiazole-4-carboxylate
• 英文别名: ethyl 2-benzylaminothiazole-4-carboxylate；Ethyl 2-(benzylamino)-1,3-thiazole-4-carboxylate
• CAS: 126534-13-2
• 化学式: C₁₃H₁₄N₂O₂S
• mdl: MFCD09335737
• 分子量: 262.332
• InChiKey: JLSAVNDMVKWSPJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  79.5
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 2-(benzylamino)thiazole-4-carboxylate 在 盐酸 、 sodium hydroxide 、 sodium hydride 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 甲醇 、 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成
  参考文献：
  名称：

  Discovery of 2-Aminothiazole-4-carboxamides, a Novel Class of Muscarinic M3 Selective Antagonists, through Solution-Phase Parallel Synthesis

  摘要：

  描述了一类新的选择性抗美洲豹M3受体拮抗剂的合成和结构-活性关系。在寻找一种结构与2-(4,4-二氟环戊基)-2-苯乙酰胺衍生物不同的抗美洲豹M3受体拮抗剂的过程中，我们在内部化学库中识别出了一种噻唑-4-氨基甲酸酯衍生物（1）作为领先化合物。由于该化合物（1）在人体结合实验中对M3受体的结合亲和力较低（Ki=140 nM），我们尝试通过组合化学方法对1进行衍生化，以提高其对M3受体的效能和对M1及M2受体的选择性。溶液相平行合成有效地促进了1的每个片段的优化。因此，我们识别出环辛烯基甲基衍生物（3e）和环壬烯基甲基衍生物（3f）作为该类抗美洲豹M3受体选择性拮抗剂的代表。

  DOI：

  10.1248/cpb.53.437
• 作为产物：
  描述：

  3-溴丙酮酸乙酯 、 N-苄基硫脲 以 乙醇 为溶剂， 生成 ethyl 2-(benzylamino)thiazole-4-carboxylate
  参考文献：
  名称：

  Discovery of 2-Aminothiazole-4-carboxamides, a Novel Class of Muscarinic M3 Selective Antagonists, through Solution-Phase Parallel Synthesis

  摘要：

  描述了一类新的选择性抗美洲豹M3受体拮抗剂的合成和结构-活性关系。在寻找一种结构与2-(4,4-二氟环戊基)-2-苯乙酰胺衍生物不同的抗美洲豹M3受体拮抗剂的过程中，我们在内部化学库中识别出了一种噻唑-4-氨基甲酸酯衍生物（1）作为领先化合物。由于该化合物（1）在人体结合实验中对M3受体的结合亲和力较低（Ki=140 nM），我们尝试通过组合化学方法对1进行衍生化，以提高其对M3受体的效能和对M1及M2受体的选择性。溶液相平行合成有效地促进了1的每个片段的优化。因此，我们识别出环辛烯基甲基衍生物（3e）和环壬烯基甲基衍生物（3f）作为该类抗美洲豹M3受体选择性拮抗剂的代表。

  DOI：

  10.1248/cpb.53.437

文献信息

• Thiazole derivatives, their preparation and their use in the treatment
  申请人：Sankyo Company Limited

  公开号：US04933355A1

  公开（公告）日：1990-06-12

  Compounds of formula (I): ##STR1## in which: R.sup.1 and R.sup.2 are independently hydrogen, alkyl, aliphatic hydrocarbon groups having one or two carbon-carbon double or treble bonds, cycloalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, alkanoyl, alkenyol, cycloalkylcarbonyol, arylcarbonyl, substituted arylcarbonyl, arylalkanoyl, substituted arylalkanoyl, arylalkenoyl, substituted arylalkenoyl, alkoxycarbonyl, aryloxycarbonyl, substituted aryloxycarbonyl, aralkyloxycarbonyl, substituted aralkyloxycarbonyl, optionally substituted carbamoyl or thiocarbamoyol, alkylsulfonyl, haloalkylsulfonyl, arylsulfonyl, substituted arylsulfonyl, alkylthio, arylthio and substituted arylthio, or R.sup.1 and R.sup.2, together with the nitrogen atom to which they are attached, form a nitrogen-containing heterocyclic group; one of R.sup.a and R.sup.b is hydrogen, alkyl or halogen, and the other of R.sup.a and R.sup.b is a group of formula (II): ##STR2## R.sup.4 is hydrogen, carboxy, protected carboxy or optionally substituted carbamoyl; R.sup.5 is hydrogen, or carboxyalkyl or protected carboxyalkyl in which the alkyl part is C.sub.1 -C.sub.6 ; n=0, 1 or 2; X is oxygen or sulfur; are useful in the treatment of the complications attendant upon diabetes and may be prepared by condensation of a thiazolidine or rhodanine compound with a compound corresponding to the remainder of the molecule of the compound of formula (I).

  式(I)的化合物：##STR1##其中：R.sup.1和R.sup.2分别是氢、烷基、具有一个或两个碳-碳双键或三键的脂肪烃基、环烷基、芳基、取代的芳基、芳基烷基、取代的芳基烷基、烷酰基、烯酰基、环烷基羰基、芳基羰基、取代的芳基羰基、芳基烷酰基、取代的芳基烷酰基、芳基烯酰基、取代的芳基烯酰基、烷氧羰基、芳氧羰基、取代的芳氧羰基、芳基烷氧羰基、取代的芳基烷氧羰基、可选地取代的氨基甲酰基或硫代氨基甲酰基、烷磺酰基、卤代烷基磺酰基、芳基磺酰基、取代的芳基磺酰基、烷硫基、芳硫基和取代的芳硫基，或R.sup.1和R.sup.2与它们连接的氮原子一起形成含氮杂环基团；R.sup.a和R.sup.b中的一个是氢、烷基或卤素，另一个是具有式(II)的基团：##STR2##R.sup.4是氢、羧基、保护羧基或可选地取代的氨基甲酰基；R.sup.5是氢，或者是碳链部分为C.sub.1-C.sub.6的羧基烷基或保护羧基烷基；n=0, 1或2；X是氧或硫；这些化合物在治疗糖尿病并发症方面是有用的，可以通过将噻唑烷或罗丹宁化合物与符合式(I)的化合物的分子余下部分对应的化合物缩合来制备。
• Thiazole derivatives, their preparation and their use in the treatment of diabetes complications
  申请人：Sankyo Company Limited

  公开号：EP0337819A1

  公开（公告）日：1989-10-18

  Compounds of formula (I): in which: R1 and R2 are independently hydrogen, alkyl, aliphatic hydrocarbon groups having one or two carbon-carbon double or treble bonds, cycloalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, alkanoyl, alkenoyl, cycloalkylcarbonyl, arylcarbonyl, substituted arylcaronyl, arylalkanoyl, substituted arylalkanoyl, arylalkenoyl, substituted arylalkenoyl, alkoxycarbonyl, aryloxycarbonyl, substituted aryloxycarbonyl, aralkyloxycarbonyl, substituted aralkyloxycarbonyl, optionally substituted carbamoyl or thiocarbamoyl, alkylsulphonyl, haloalkylsulphonyl, arylsulphonyl, substituted arylsulphonyl, alkylthio, arylthio and substituted arylthio, or R1 and R2, together with the nitrogen atom to which they are attached, form a nitrogen-containing heterocyclic group; one of Ra and Rb is hydrogen, alkyl or halogen, and the other of Ra and Rb is a group of formula (II): R4 is hydrogen, carboxy, protected carboxy or optionally substituted carbamoyl; R5 is hydrogen, or carboxyalkyl or protected carboxyalkyl in which the alkyl part is C1 -Cs; n = 0, 1 or 2; X is oxygen or sulphur; are useful in the treatment of the complications attendant upon diabetes and may be prepared by condensation of a thiazolidine or rhodanine compound with a compound corresponding to the remainder of the molecule of the compound of formula (I).

  式(I)化合物： 其中 R1 和 R2 独立地为氢、烷基、具有一个或两个碳碳双键或三键的脂族烃基、环烷基、芳基、取代芳基、烷酰基、烯酰基、环烷基羰基、芳基羰基、取代芳基羰基、芳基烷酰基、取代芳基烷酰基、芳基烯酰基、取代芳基烯酰基、烷氧基羰基、芳氧基羰基、芳氧基羰基、芳烷氧基羰基、取代芳氧基羰基、芳烷氧基羰基、芳烷氧基羰基、取代芳烷氧基羰基、选择性取代氨基甲酰基或硫代氨基甲酰基、烷氧基羰基、芳氧基羰基、取代的芳氧基羰基、烷氧基羰基、取代的芳氧基羰基、任选取代的氨基甲酰基或硫代氨基甲酰基、烷基磺酰基、卤代烷基磺酰基、芳基磺酰基、取代的芳基磺酰基、烷硫基、芳硫基和取代的芳硫基，或 R1 和 R2 与它们所连接的氮原子一起形成含氮杂环基团；Ra 和 Rb 中的一个是氢、烷基或卤素，Ra 和 Rb 中的另一个是式 (II) 基团： R4 是氢、羧基、受保护的羧基或任选取代的氨基甲酰基；R5 是氢、羧基烷基或受保护的羧基烷基，其中烷基部分是 C1-Cs；n = 0、1 或 2；X 是氧或硫； 可通过噻唑烷或罗丹宁化合物与对应于式（I）化合物分子剩余部分的化合物缩合制备。
• US4933355A
  申请人：——

  公开号：US4933355A

  公开（公告）日：1990-06-12
• Discovery of 2-Aminothiazole-4-carboxamides, a Novel Class of Muscarinic M3 Selective Antagonists, through Solution-Phase Parallel Synthesis
  作者：Yufu Sagara、Morihiro Mitsuya、Minaho Uchiyama、Yoshio Ogino、Toshifumi Kimura、Norikazu Ohtake、Toshiaki Mase

  DOI：10.1248/cpb.53.437

  日期：——

  Synthesis and structure–activity relationship of a new class of muscarinic M3 selective antagonists were described. In the course of searching for a muscarinic M3 antagonist with a structure distinct from those of the 2-(4,4-difluorocyclopentyl)-2-phenylacetamide derivatives, we identified a thiazole-4-carboxamide derivative (1) as a lead compound in our in-house chemical collection. Since this compound (1) showed relatively low binding affinity (Ki=140 nM) for M3 receptors in the human binding assays, we tried to improve its potency and selectivity for M3 over M1 and M2 receptors by derivatization of 1 through a combinatorial approach. A solution-phase parallel synthesis effectively contributed to the optimization of each segment of 1. Thus, we have identified a cyclooctenylmethyl derivative (3e) and a cyclononenylmethyl derivative (3f) as representative M3 selective antagonists in this class.

  描述了一类新的选择性抗美洲豹M3受体拮抗剂的合成和结构-活性关系。在寻找一种结构与2-(4,4-二氟环戊基)-2-苯乙酰胺衍生物不同的抗美洲豹M3受体拮抗剂的过程中，我们在内部化学库中识别出了一种噻唑-4-氨基甲酸酯衍生物（1）作为领先化合物。由于该化合物（1）在人体结合实验中对M3受体的结合亲和力较低（Ki=140 nM），我们尝试通过组合化学方法对1进行衍生化，以提高其对M3受体的效能和对M1及M2受体的选择性。溶液相平行合成有效地促进了1的每个片段的优化。因此，我们识别出环辛烯基甲基衍生物（3e）和环壬烯基甲基衍生物（3f）作为该类抗美洲豹M3受体选择性拮抗剂的代表。
• Ethyl 2-((4-Chlorophenyl)amino)thiazole-4-carboxylate and Derivatives Are Potent Inducers of Oct3/4
  作者：Xinlai Cheng、Hiroki Yoshida、Dena Raoofi、Sawsan Saleh、Hamed Alborzinia、Frank Wenke、Axel Göhring、Stefanie Reuter、Nancy Mah、Heiko Fuchs、Miguel A. Andrade-Navarro、James Adjaye、Sheraz Gul、Jochen Utikal、Ralf Mrowka、Stefan Wölfl

  DOI：10.1021/acs.jmedchem.5b00226

  日期：2015.8.13

  The octamer-binding transcription factor 4 (Oct3/4) is a master gene in the transcriptional regulatory network of pluripotent cells. Repression of Oct3/4 in embryonic stem cells (ESCs) is associated with cell differentiation and loss of pluripotency, whereas forced overexpression in cooperation with other transcriptional factors, such as Nanog, Sox2, and Lin28, can reprogram somatic cells back into pluripotent cells, termed induced pluripotent stem cells (iPSCs). However, random integration and potential tumorigenic transformation caused by viral transduction limit the clinical application of iPSCs. By performing a cell-based high throughput screening (HTS) campaign, we identified several potential small molecules as inducers of Oct3/4 expression. Here we report a lead structure ethyl 2-((4-chlorophenyl)amino)- thiazole-4-carboxylate, termed O4I2, showing high activity in enforcing Oct3/4 expression. On the basis of chemical expansion, we further identified derivatives having increased activities toward Oct3/4 induction. Thus, O4I2 and its derivatives should provide a new class of small molecules suitable for iPSC generation.